MYC-Driven Pathways in Breast Cancer Subtypes

Deming, 2000, C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance, Br. J. Cancer, 83, 1688, 10.1054/bjoc.2000.1522

Blancato, 2004, Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses, Br. J. Cancer, 90, 1612, 10.1038/sj.bjc.6601703

Prall, 1998, C-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry, Mol. Cell. Biol., 18, 4499, 10.1128/MCB.18.8.4499

Hanson, 1994, Effects of c-myc expression on cell cycle progression, Mol. Cell. Biol., 14, 5748

Meyer, 2008, Reflecting on 25 years with MYC, Nat. Rev. Cancer, 8, 976, 10.1038/nrc2231

Dang, 2012, MYC on the path to cancer, Cell, 149, 22, 10.1016/j.cell.2012.03.003

Hartl, 2016, The Quest for Targets Executing MYC-Dependent Cell Transformation, Front. Oncol., 6, 132, 10.3389/fonc.2016.00132

Jemal, 2011, Global cancer statistics, CA Cancer J. Clin., 61, 69, 10.3322/caac.20107

Schnipper, 1986, Clinical implications of tumor-cell heterogeneity, N. Engl. J. Med., 314, 1423, 10.1056/NEJM198605293142206

Matsen, 2013, Breast cancer: A review for the general surgeon, JAMA Surg., 148, 971, 10.1001/jamasurg.2013.3393

Hammond, 2010, American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J. Clin. Oncol., 28, 2784, 10.1200/JCO.2009.25.6529

Allegra, 1980, Changes in multiple or sequential estrogen receptor determinations in breast cancer, Cancer, 45, 792, 10.1002/1097-0142(19800215)45:4<792::AID-CNCR2820450430>3.0.CO;2-X

Liesenfeld, 2013, Review of mass spectrometry-based metabolomics in cancer research, Cancer Epidemiol. Biomark. Prev., 22, 2182, 10.1158/1055-9965.EPI-13-0584

Ward, 2012, Metabolic reprogramming: A cancer hallmark even warburg did not anticipate, Cancer Cell, 21, 297, 10.1016/j.ccr.2012.02.014

Anderson, 2002, Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database, Breast Cancer Res. Treat., 76, 27, 10.1023/A:1020299707510

Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J. Clin. Oncol., 20, 3396, 10.1200/JCO.2002.10.057

Clarke, 2009, Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells, J. Steroid Biochem. Mol. Biol., 114, 8, 10.1016/j.jsbmb.2008.12.023

Clarke, 1994, Hormonal carcinogenesis in breast cancer: Cellular and molecular studies of malignant progression, Breast Cancer Res. Treat., 31, 237, 10.1007/BF00666157

Buzdar, 1996, Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group, J. Clin. Oncol., 14, 2000, 10.1200/JCO.1996.14.7.2000

Shang, 2000, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription, Cell, 103, 843, 10.1016/S0092-8674(00)00188-4

Cook, 2014, MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer, Mol. Cancer, 13, 239, 10.1186/1476-4598-13-239

McNeil, 2006, c-Myc overexpression and endocrine resistance in breast cancer, J. Steroid Biochem. Mol. Biol., 102, 147, 10.1016/j.jsbmb.2006.09.028

Chen, 2015, Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells, J. Steroid Biochem. Mol. Biol., 149, 118, 10.1016/j.jsbmb.2015.02.004

Wang, 2011, Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor, Mol. Endocrinol., 25, 1527, 10.1210/me.2011-1037

Miller, 2011, A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance, Clin. Cancer Res., 17, 2024, 10.1158/1078-0432.CCR-10-2567

Sengupta, 2014, Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers, Breast Cancer Res. Treat., 143, 113, 10.1007/s10549-013-2789-2

Butt, 2008, The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome, Breast Cancer Res., 10, R28, 10.1186/bcr1985

Zhang, 2014, HSPC111 governs breast cancer growth by regulating ribosomal biogenesis, Mol. Cancer Res., 12, 583, 10.1158/1541-7786.MCR-13-0168

Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106

Hsu, 2016, The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer, Cancer Metastasis Rev., 35, 575, 10.1007/s10555-016-9649-6

Ross, 2009, The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine, Oncologist, 14, 320, 10.1634/theoncologist.2008-0230

Esteva, 2010, Molecular predictors of response to trastuzumab and lapatinib in breast cancer, Nat. Rev. Clin. Oncol., 7, 98, 10.1038/nrclinonc.2009.216

Gogas, 2016, MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer, J. Transl. Med., 14, 136, 10.1186/s12967-016-0883-z

Venturutti, 2016, MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1, Oncogene, 35, 6189, 10.1038/onc.2016.151

Collins, 2015, Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer, Oncogene, 34, 525, 10.1038/onc.2013.586

Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412

Horiuchi, 2014, Taking on challenging targets: Making MYC druggable, Am. Soc. Clin. Oncol. Educ. Book, 34, e497, 10.14694/EdBook_AM.2014.34.e497

Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat. Rev. Cancer, 5, 689, 10.1038/nrc1691

Horiuchi, 2012, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, J. Exp. Med., 209, 679, 10.1084/jem.20111512

Gross, 2014, Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer, Mol. Cancer Ther., 13, 890, 10.1158/1535-7163.MCT-13-0870

Knudsen, 2015, RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer, Cell Cycle, 14, 109, 10.4161/15384101.2014.967118

Ren, 2013, MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency, Tumour Biol., 34, 3945, 10.1007/s13277-013-0983-9

Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055

Shen, 2015, Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP, Proc. Natl. Acad. Sci. USA, 112, 5425, 10.1073/pnas.1501555112

Pereira, 2016, MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer, Clin. Breast Cancer, 17, 188, 10.1016/j.clbc.2016.12.005

Pan, 2016, Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells, Environ. Health Perspect., 124, 563, 10.1289/ehp.1409200